<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                Part 310: New Drugs
                            </h3>
                            <table>
  <thead>
    <tr>
      <th scope="col">Section No.</th>
      <th scope="col">Description</th>
    </tr>
  </thead>
  <tbody>
    
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.3.html">
                        Section 310.3
                        </a>
                  </td>
                  <td scope="row">Definitions and interpretations</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.4.html">
                        Section 310.4
                        </a>
                  </td>
                  <td scope="row">Biologics; products subject to license control</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.6.html">
                        Section 310.6
                        </a>
                  </td>
                  <td scope="row">Applicability of ``new drug'' or safety or effectiveness findings in drug efficacy study implementation notices and notices of</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.100.html">
                        Section 310.100
                        </a>
                  </td>
                  <td scope="row">New drug status opinions; statement of policy</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.103.html">
                        Section 310.103
                        </a>
                  </td>
                  <td scope="row">New drug substances intended for hypersensitivity testing</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.200.html">
                        Section 310.200
                        </a>
                  </td>
                  <td scope="row">Prescription-exemption procedure</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.201.html">
                        Section 310.201
                        </a>
                  </td>
                  <td scope="row">Exemption for certain drugs limited by new-drug applications to prescription sale</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.303.html">
                        Section 310.303
                        </a>
                  </td>
                  <td scope="row">Continuation of long-term studies, records, and reports on certain drugs for which new drug applications have been approved</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.305.html">
                        Section 310.305
                        </a>
                  </td>
                  <td scope="row">Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.305.html">
                        Section 310.305
                        </a>
                  </td>
                  <td scope="row">Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.501.html">
                        Section 310.501
                        </a>
                  </td>
                  <td scope="row">Patient package inserts for oral contraceptives</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.502.html">
                        Section 310.502
                        </a>
                  </td>
                  <td scope="row">Certain drugs accorded new drug status through rulemaking procedures</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.503.html">
                        Section 310.503
                        </a>
                  </td>
                  <td scope="row">Requirements regarding certain radioactive drugs</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.509.html">
                        Section 310.509
                        </a>
                  </td>
                  <td scope="row">Parenteral drug products in plastic containers</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.515.html">
                        Section 310.515
                        </a>
                  </td>
                  <td scope="row">Patient package inserts for estrogens</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.517.html">
                        Section 310.517
                        </a>
                  </td>
                  <td scope="row">Labeling for oral hypoglycemic drugs of the sulfonylurea class</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.518.html">
                        Section 310.518
                        </a>
                  </td>
                  <td scope="row">Drug products containing iron or iron salts</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.519.html">
                        Section 310.519
                        </a>
                  </td>
                  <td scope="row">Drug products marketed as over-the-counter (OTC) daytime sedatives</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.527.html">
                        Section 310.527
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for external use as hair growers or for hair</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.528.html">
                        Section 310.528
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for use as an aphrodisiac</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.529.html">
                        Section 310.529
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for oral use as insect repellents</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.530.html">
                        Section 310.530
                        </a>
                  </td>
                  <td scope="row">Topically applied hormone-containing drug products for over-the-counter (OTC) human use</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.531.html">
                        Section 310.531
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for the treatment of boils</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.532.html">
                        Section 310.532
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) to relieve the symptoms of benign prostatic</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.533.html">
                        Section 310.533
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for human use as an anticholinergic in</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.534.html">
                        Section 310.534
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for human use as oral wound healing agents</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.536.html">
                        Section 310.536
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for use as a nailbiting or thumbsucking deterrent</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.537.html">
                        Section 310.537
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for oral administration for the treatment of</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.538.html">
                        Section 310.538
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for use for ingrown toenail relief</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.540.html">
                        Section 310.540
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for use as stomach acidifiers</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.541.html">
                        Section 310.541
                        </a>
                  </td>
                  <td scope="row">Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hypophosphatemia</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.542.html">
                        Section 310.542
                        </a>
                  </td>
                  <td scope="row">Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.543.html">
                        Section 310.543
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for human use in exocrine pancreatic insufficiency</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.544.html">
                        Section 310.544
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for use as a smoking deterrent</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.545.html">
                        Section 310.545
                        </a>
                  </td>
                  <td scope="row">Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.546.html">
                        Section 310.546
                        </a>
                  </td>
                  <td scope="row">Drug products containing active ingredients offered over-the-counter (OTC) for the treatment and/or prevention of nocturnal</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.547.html">
                        Section 310.547
                        </a>
                  </td>
                  <td scope="row">Drug products containing quinine offered over-the-counter (OTC) for the treatment and/or prevention of malaria</td>
                </tr>
                
                <tr>
                  <td scope="row"><a href="../sections/21CFR310.548.html">
                        Section 310.548
                        </a>
                  </td>
                  <td scope="row">Drug products containing colloidal silver ingredients or silver salts offered over-the-counter (OTC) for the treatment</td>
                </tr>
                
  </tbody>
</table>

      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
